Tempest Therapeutics (TPST)
(Real Time Quote from BATS)
$3.46 USD
-0.08 (-2.26%)
Updated Apr 29, 2024 03:37 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
TPST 3.46 -0.08(-2.26%)
Will TPST be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TPST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TPST
Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
All You Need to Know About Tempest Therapeutics, Inc. (TPST) Rating Upgrade to Buy
TPST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?
Bears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' Now
Other News for TPST
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
Largest borrow rate increases among liquid names
Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting